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Objectives: To test the reliability, validity and
responsiveness of the 13-item Shortness of Breath
with Daily Activities (SOBDA) questionnaire, and
determine the threshold for response and minimal
important difference (MID).
Design: 6 week, randomised, double-blind, placebo-
controlled study.
Setting: 40 centres in the USA between 29 October
2009 and 1 July 2010.
Primary and secondary outcome measures: 547
patients with chronic obstructive pulmonary disease
(COPD) were enrolled and 418 entered the 2-week run-
in period. Data from the run-in period were collected to
test internal consistency, test–retest reliability,
convergent validity and known-groups validity of the
SOBDA. Three hundred and sixty six patients were
randomised 2:2:1 to fluticasone propionate/salmeterol
250/50 µg, salmeterol 50 µg or placebo, twice daily.
Results from the SOBDA questionnaire, Patient Global
Assessment of Change Question, modified Medical
Research Council Dyspnoea Scale (mMRC), Clinician
Global Impression of Dysponea Severity (CGI-S),
Clinician Global Impression of Change Question and
Chronic Respiratory Disease Questionnaire self-
administered standardised version (CRQ-SAS) were
evaluated; spirometry and safety parameters were
measured. Study endpoints were selected to investigate
the cross-sectional and longitudinal validity of the
SOBDA questionnaire in relation to the clinical criteria.
Results: Internal consistency of the SOBDA
questionnaire (Cronbach α) was 0.89. Test–retest
reliability (intraclass correlation) was 0.94. The SOBDA
weekly scores correlated with the patient-reported and
clinician-reported mMRC, CGI-S and CRQ-SAS
dyspnoea domain scores (0.29, 0.24, 0.24 and –0.68,
respectively). The SOBDA weekly scores differentiated
between the responders and the non-responders as
rated by the patients and the clinicians. Anchor-based
and supportive distribution-based analyses produced a
range of the potential values for the threshold for the
responders and MID.
Conclusions: The 13-item SOBDA questionnaire is
reliable, valid and responsive to change in patients with
COPD. On using anchor-based methods, the proposed
responder threshold shows a −0.1 to −0.2 score
change. A specific threshold value will be identified as
more data are generated from future clinical trials.
Trial registration: NCT00984659; GlaxoSmithKline
study number: ASQ112989.
INTRODUCTION
Dyspnoea, sometimes referred to as ‘shortness
of breath’ or ‘breathlessness’ by the patient, is
a common and significant symptom of patients
with chronic obstructive pulmonary disease
(COPD). In one survey of 3000 patients with
COPD, 56% were found to have breathlessness
during normal physical activities and 42%
reported breathlessness while doing house-
hold chores.1
Capturing the effect of a treatment inter-
vention on dyspnoea from the patient’s per-
spective is therefore an important objective
in order to demonstrate treatment effective-
ness. While patient-reported aspects of
COPD have been assessed using currently
available instruments, most do not
adequately address the concept of dyspnoea
in patients with COPD for use in clinical
ARTICLE SUMMARY
Strengths and limitations of the study
▪ This study reconfirmed the initial psychometric
validation observed in the non-interventional
study (A2-4398-003).2
▪ Only patients with modified Medical Research
Council Dyspnoea Scale ≥2 were included in the
patient population, thereby restricting the short-
ness of breath severity range.
▪ Approximately half of the patients did not answer
the last Patient Global Assessment of Change
question thereby possibly affecting some validity
assessments.
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trials, due to the limited assessment of psychometric
properties during development of the questionnaire or
inconsistent clinical validity in use. In addition, there are
no currently available instruments for assessing
COPD-related dyspnoea that can support a specific label
claim for a medicinal product in the USA.
The Shortness of Breath with Daily Activities
(SOBDA) questionnaire is a daily diary questionnaire
developed to quantify a patient’s perception of dyspnoea
related to daily activities and how this changes over time
during treatment.2 3 Development of the SOBDA ques-
tionnaire followed the Patient-Reported Outcomes
Guidance for drug development issued by the US Food
and Drug Administration4 and included the creation of
an endpoint rationale and the development of a concep-
tual framework.3 Qualitative research, including individ-
ual interviews and patient focus groups, was used to
develop potential questions (item pool), item format
and response options, which were subject to clinical and
translation expert review. Further cognitive interviews
with patients were conducted to test content validity.3
The item pool was tested in a non-interventional study,
and the number of items was appropriately reduced to
produce the final SOBDA questionnaire.2 Initial psycho-
metric validation from this non-interventional study
showed excellent internal consistency and test–retest
reliability.2
The objectives of this study were to (1) confirm reli-
ability and validity, (2) evaluate the responsiveness, (3)
define the threshold for the responders and also the
minimal important difference (MID) of the final
SOBDA questionnaire in patients with COPD. The
threshold for response was established by comparing the
SOBDA change scores for the responders and the non-
responders, defined according to a range of established
patient-completed and clinician-completed assessments.
The study included active treatments to ensure that
some patients would be classified as ‘responders’ based
on the established clinical measures.
METHODS
Patients
Male and female patients ≥40 years of age with an estab-
lished clinical history of COPD in accordance with the
American Thoracic Society/European Respiratory
Society definitions5 were recruited. At screening, the
patients were required to have a postsalbutamol forced
expiratory volume in 1 s (FEV1) ≤70% of the predicted
normal and FEV1/forced vital capacity (FVC) ratio of
<0.70; to be a current or former smoker with a history of
at least 10 pack-years; and to demonstrate evidence of
dyspnoea as assessed by a patient-reported modified
Medical Research Council Dyspnoea Scale (mMRC)
score ≥2. The study protocol was institutional review
board approved and all the patients provided written
informed consent before enrolment.
Study design
This randomised, double-blind, placebo-controlled study
was conducted at 40 centres in the USA from 29
October 2009 to 01 July 2010 (trial registration:
NCT00984659; GlaxoSmithKline study number:
ASQ112989). Patients attended three clinic visits. At
screening visit 1, eligible patients entered a 2-week
run-in period during which short-acting bronchodilator
rescue medications (salbutamol and/or ipratropium)
were permitted. At visit 2, eligible patients were rando-
mised (2:2:1) to receive fluticasone propionate/salme-
terol combination (FSC) 250/50 µg, salmeterol (SAL)
50 µg or placebo, all administered twice daily via a
DISKUS inhaler, for 6 weeks. The FSC and SAL active
treatments were included to potentially induce a change
in the degree of the patients’ symptoms of dyspnoea,
which would allow the responsiveness of the SOBDA
questionnaire to be assessed. The final dose of study
medication was taken on the day before visit 3 (week 6).
In the event of a patient not completing the week 6 visit,
attempts were made for the patient to attend an early
withdrawal visit that included the week 6 assessments.
All non-COPD medications, including pre-existing
selective β-blocker therapy, could be continued if their
dose remained constant. The concurrent use of inhaled
or oral corticosteroids, long-term oxygen therapy, long-
acting bronchodilators and theophylline were the exclu-
sion criteria within the study protocol.
Measurements and assessments
Patient-completed measures: SOBDA questionnaire
The 13-item SOBDA questionnaire (box 1) was com-
pleted in an electronic diary (e-diary) each evening
Box 1 13-Item Shortness of Breath with Daily Activities
(SOBDA) questionnaire
How short of breath were you when
▸ You put on long pants or stockings?
▸ You put on your shoes (sandals)?
▸ You washed yourself?
▸ You reached above your head to put things away?
▸ You cleaned or fixed something at floor level?
▸ You put things away in the cupboard or shelf at chest level?
▸ You put things away in the cupboard or shelf at knee level?
▸ You prepared food or a meal?
▸ You picked up light objects off the floor?
▸ You carried objects at your side like bags or baskets?
▸ You walked at a slow pace?
▸ You walked up 3 stairs?
▸ You walked up 8 stairs?
Response options included
▸ I did not do the activity today




▸ So severely that I did not do the activity today
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immediately before bedtime, which allowed the patient
to reflect on and capture the current day’s activities.2 3
All items followed the same format: ‘How breathless
were you when [completing the specified activity]?’
Individual item responses are completed on a scale from
‘not at all’ to ‘so short of breath that I did not do the
activity’. Items 1–4, 6, 8, 9, 11 and 12 are scored from 1
(‘not at all’), 2 (‘slightly’), 3 (‘moderately’) to 4
(‘severely’ or ‘so severely that I did not do the activity
today’), and items 5, 7, 10 and 13 are scored from 1
(‘not at all’ and ‘slightly’), 3 (‘moderately’) and 4
(‘severely’ or ‘so severely that I did not do the activity
today’). Patients were also given an option of ‘did not
do’ for activities they did not perform for other reasons.
In scoring the questionnaire, these responses were
regarded as missing data. Owing to the design of the
e-diary, it was not possible for the patients to skip indi-
vidual questions within the diary, although a full day of
data could be missed if the patient did not access the
diary within the time window allowed.
Analyses were conducted aggregating daily data over
weekly time periods to account for day-to-day variability
and the fact that not all the activities were performed
every day. A daily SOBDA score was computed across the
13 items as a mean score ranging from 1 to 4, if at least
7 items had non-missing scores. A weekly mean SOBDA
score was then computed as the mean of the daily mean
scores in a 7-day period, if at least 4 of7 days had non-
missing SOBDA daily scores. The baseline SOBDA
weekly score for each patient was calculated as the mean
value during the week before randomisation.
Patient-completed measures: other
Additional questions were completed via an e-diary, daily
or weekly. Daily questions included any form of contact
with healthcare professionals, frequency of rescue medi-
cation use and completion of a Global Assessment of
Shortness of Breath question: ‘Overall, were you short of
breath during your activities today?’ Patients responded
to this question on a 5-point scale from ‘1=not at all’ to
‘5=extremely’. Every 7 days, patients responded to a
Patient Global Assessment of Change (PGAC) question
that asked, ‘Compared with last week (7 days ago), how
was your shortness of breath today?’ on a scale of
‘1=much worse’ to ‘5=much better’, with 3=‘no change’.
Patients completed the mMRC at each clinic visit and
the 20-item Chronic Respiratory Disease Questionnaire
self-administered standardised version (CRQ-SAS) at visit
2 and week 6/early withdrawal.
Clinician-completed assessments
A Clinician Global Impression of Dysponea Severity
(CGI-S) question to assess dyspnoea severity on a scale
of 1 (mild) to 4 (very severe) was completed at visit 2
and week 6/early withdrawal. A CGI of Change (CGI-C)
question to assess change in dyspnoea on a scale of 1
(much worse) to 5 (much better), with 3 being no
change, was completed at week 6/early withdrawal.
Clinicians rated the patient’s dyspnoea on the 5-point
mMRC scale at each clinic visit.
Spirometry
Spirometry (FEV1 and FVC) was performed at all clinic
visits after the questionnaires were completed. FEV1
responders were defined as patients who had a change
of ≥100 mL from visit 2 to week 6/early withdrawal,
whereas FEV1 non-responders were those patients with a
change of <100 mL. Bronchodilator reversibility testing
was also performed 30 min postsalbutamol (360 µg) at
screening. The predicted FEV1 values were calculated
according to the National Health and Nutrition
Examination Survey III reference values.6
Safety
Safety was assessed by the reported adverse events (AEs)
and COPD exacerbations.
Statistical analyses
Sample size and powering
Sample size calculations were based on the evaluation of
the responsiveness of the SOBDA questionnaire2 3 and
allowed for comparison of the SOBDA change scores for
the responders and the non-responders. Calculations
assumed 90% power, a two-sided 5% significance level
and a standardised between-groups effect size of 0.5
(defined as the difference between the responders and
the non-responders divided by the SD of the difference).
The sample size was increased to allow exploratory com-
parisons of the SOBDA scores between treatment arms.
Assuming that 90% of randomised patients would
provide sufficient data for this comparison and a ran-
domisation ratio of 2:2:1, approximately 350 patients
were planned for randomisation in order to provide 320
evaluable patients.
Analyses for the internal consistency, test–retest reliabil-
ity in a stable population, convergent validity and
known-groups validity were based on the data collected
from the run-in population. This population consisted of
randomised and non-randomised patients who had com-
pleted visit 2. The responsiveness to change of the SOBDA
questionnaire was based on data collected from the modi-
fied intent-to-treat (mITT) population, defined as all
patients who were randomised to treatment and who
received at least one dose of the study drug, and were ana-
lysed according to the treatment actually received if this
was different from the randomised treatment assignment.
Internal consistency
To confirm the reliability and validity of the SOBDA
questionnaire,2 the internal consistency of the instru-
ment was assessed and summary scores were compared
with other endpoints collected.
The internal consistency of the SOBDA score was
assessed for patients with a non-missing score for each
item at day 1 of the run-in period by using Cronbach’s
formula for coefficient α (scale from 0 to 1.0); a value of
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0.70 or greater is recognised as indicating acceptable
internal consistency for an instrument.7 Pearson’s correl-
ation coefficient and intraclass correlation coefficient
(ICC) were used to evaluate test–retest reliability, com-
paring the SOBDA weekly scores for patients who
reported no change on their weekly PGAC assessment
during weeks 1 and 2 of the run-in period.
Convergent and known-groups validity
The SOBDA weekly scores were compared with the
other relevant study measures to establish the conver-
gent and known-groups validity of the instrument.
Convergent validity was assessed by examining the
Spearman rank order correlation coefficient between
the baseline SOBDA weekly score and the mMRC
(patient and clinician) ratings and CGI-S ratings at visit
2. Pearson’s correlation coefficient between the baseline
SOBDA weekly scores and the CRQ-SAS dyspnoea
domain score at visit 2 was also assessed. Known-groups
validity, demonstrating that groups of patients who are
known to be different report different SOBDA scores,
was assessed by comparisons of SOBDA weekly scores
between groups of patients based on the mMRC
(patient and clinician) ratings and CGI-S ratings col-
lected at visit 2 using analysis of covariance (ANCOVA)
models adjusted for age, gender and FEV1% predicted
measured during the screening visit.
Responsiveness
Responsiveness of the SOBDA questionnaire was assessed
by comparing score changes between the responders and
the non-responders on the PGAC, CGI-C and CRQ-SAS
dyspnoea domain and mMRC. Responders by PGAC and
CGI-C were defined as patients with a rating of ‘better’ or
‘much better’, and non-responders were defined as
patients with a response of ‘much worse,’ ‘worse’ or ‘no
change’, on their respective scales. A CRQ-SAS dyspnoea
domain responder was defined as a patient with a score
increase of 0.5 unit or more between visit 2 and week 6/
early withdrawal, and a non-responder was defined as a
patient who had a decrease in score or an increase of less
than 0.5 unit. A responder by mMRC was defined as a
patient who had a score decrease of 1 unit or more
between visit 2 and week 6/early withdrawal, and a non-
responder was defined as a patient who had the same
score or an increase in score.
Changes from the previous week to the current week’s
SOBDA score during the six-week study treatment period
were compared for the responders and the non-
responders (defined according to the corresponding
weekly PGAC assessment) using ANCOVA, adjusted for
age, gender and the baseline SOBDAweekly score. In add-
ition, changes in the mean SOBDA scores during the last
week of the treatment were compared for the responders
and the non-responders based on the PGAC, CGI-C and
CRQ-SAS dyspnoea domain, clinician-completed mMRC
and patient-completed mMRC using ANCOVA adjusted
for age, sex and the baseline SOBDAweekly score.
Defining the threshold for SOBDA responders and MID
A preliminary MID for SOBDA mean score change within
a participant was also determined. This threshold for the
SOBDA response allowed a comparison of the proportions
of responders in different intervention groups or treat-
ment categories. Anchor-based methods using the PGAC,
CGI-C and CRQ-SAS dyspnoea domain scores were used
to establish the threshold for the SOBDA responders and
the MID, by calculating SOBDA weekly change scores (for
PGAC) and changes in SOBDA weekly scores from base-
line to the last week of treatment (for the PGAC, CGI-C
and CRQ-SAS dyspnoea domain and FEV1) in the
response category or prespecified grouping of ‘better’ for
each anchor. Cumulative distribution plots based on these
anchors were also used to determine the MID.
Post hoc supportive analyses using distribution-based
approaches were also conducted after completion of the a
priori specified anchor-based analyses to further supple-
ment estimation of a responder threshold. A method
described by Revicki et al8 was used to estimate the
response threshold by calculating 0.2 and 0.3 times the SD
of the SOBDA scores at baseline. In addition, thresholds
were calculated by the SE of the measurements method.9
RESULTS
A total of 547 patients were screened and 418 completed
week 2 (screening visit 1) and week 0 (randomisation,
visit 2) assessments; 52 patients were not eligible for ran-
domisation. 366 patients met the inclusion criteria and
were randomised; however, one patient refused to take
study medication; thus, 365 patients received treatment
and were included in the mITT (figure 1). Patients were
predominantly white (90%), male (57%) with a mean
age of 61.1 years (SD, 9.7 years) and a mean body mass
index of 28.3 kg/m2 (table 1). The majority (62%) of
patients were current smokers with an extensive smoking
history (mean pack-years, 54.9). The mean postsalbuta-
mol % predicted FEV1 was 49.9%, indicative of a popula-
tion with a severe airflow obstruction.
A total of 29 patients withdrew from the study (FSC
9%, SAL 7% and placebo 8%), 13 because of an AE
(FSC 5%, SAL 2% and placebo 4%).
Reliability and validity
Internal consistency
Cronbach’s α value for SOBDA was 0.89 (n=344). Test–
retest reliability was assessed between weeks 1 and 2 of
the run-in period for the 152 patients reporting no
change on the second weekly PGAC assessment:
Pearson’s correlation coefficients and ICC were both
0.94, with a mean difference between weeks 1 and 2 of
0.01 on the 4-point SOBDA scale.
Convergent validity
The relationship of the SOBDA weekly scores to patient-
reported and clinical assessments of the dyspnoea sever-
ity or constructs hypothetically related to the dyspnoea
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severity was examined to assess convergent validity. The
Spearman rank-order correlations between the baseline
SOBDA weekly scores and mMRC scores were 0.29
(patient reported) and 0.24 (clinician reported), and it
was 0.24 for CGI-S. Pearson’s correlation between the
baseline SOBDA weekly scores and the CRQ-SAS dys-
pnoea domain score was −0.68 (higher scores in
CRQ-SAS, contrary to SOBDA, indicate less dyspnoea
and hence the correlation is negative).
Known-groups validity
The known-groups validity was evaluated by determining the
extent to which the baseline SOBDA weekly scores differen-
tiated between patients with varying levels of dyspnoea sever-
ity as rated on the patient-reported and clinician-reported
mMRC and CGI-S collected at visit 2. The least-squares
mean SOBDA weekly scores were increased as the CGI-S
and mMRC clinician/patient ratings increased (table 2).
Responsiveness
The SOBDAweekly scores were lower in the PGAC respon-
ders than in the non-responders, indicating less dyspnoea
with daily activities. Differences between the SOBDA
weekly change scores for the PGAC responders and non-
responders were statistically significant for each weekly
comparison with the exception of week 6 (table 3A).
Changes in the SOBDA weekly score between baseline
and the last treatment week were statistically significantly
larger for the CGI-C and CRQ-SAS dyspnoea domain
responders than for the non-responders (p<0.001). This
Figure 1 Patient disposition. *Patients who completed visits 1 and 2 including those not randomised. †Patients randomised to
treatment and received at least one dose of the study drug. One additional patient was randomised but not treated. BID, twice
daily; FSC, fluticasone propionate/salmeterol combination; mITT, modified intent-to-treat; SAL, salmeterol.
Table 1 Demographic and clinical characteristics
Not randomised Placebo FSC 250/50 µg SAL 50 µg Total
N 52 75 139 152 418
Age, year (mean (SD)) 63.8 (9.6) 62.8 (9.8) 60.2 (9.5) 60.1 (9.6) 61.1 (9.7)
Male, n (%) 25 (48) 46 (61) 79 (57) 89 (59) 239 (57)
White, n (%) 44 (85) 65 (87) 127 (91) 140 (92) 376 (90)
Current smoker, n (%) 29 (57) 46 (61) 84 (60) 99 (65) 258 (62)
Body mass index, mean (SD) 28.3 (6.9) 26.6 (6.1) 29.0 (7.3) 28.5 (6.2) 28.3 (6.7)
Postbronchodilator FEV1% predicted mean (SD) 50.3 (15.1) 49.4 (13.1) 49.5 (13.7) 50.2 (13.8) 49.9 (13.8)
FEV1/FVC % (mean (SD)) 55.7 (35.2) 51.6 (11.4) 53.7 (11.4) 52.2 (10.9) 53.0 (16.1)
Percentage of reversibility (mean (SD)) 8.6 (14.4) 16.7 (19.2) 14.5 (18.5) 11.7 (13.9) 13.1 (16.8)
The ‘not randomised’ column reflects those patients who completed the visit 1 and 2 assessments but were not eligible to be randomised.
The ‘total’ column reflects the run-in population, defined as patients who completed visits 1 and 2, including those who were not randomised.
FEV1, forced expiratory volume in 1 s; FSC, fluticasone propionate/salmeterol combination; FVC, forced vital capacity; SAL, salmeterol.
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was not seen with the patient-completed or clinician-
completed mMRC or PGAC defined responders,
although changes in the last treatment week SOBDA
scores were numerically larger for the responders versus
the non-responders (table 3B).
Threshold for SOBDA responders and MID
Patients classified as ‘better’ based on the CGI-C,
CRQ-SAS dyspnoea domain (change of >0 to 0.5 units)
or FEV1 (change of >50 to <100 mL) had a mean
change in the SOBDA score of –0.25, –0.13 or –0.16,
respectively, at the last treatment week compared with
the baseline. Patients who rated their dyspnoea as
‘better’ on the PGAC assessments had a mean change in
the SOBDA score of –0.26 at week 1, −0.08 at weeks 2, 3
and 5, –0.10 at week 4 and –0.05 at week 6.
By using the method described by Revicki et al,8
thresholds of –0.14 and –0.21 were calculated by using
0.2 and 0.3 times the SD of the SOBDA scores at base-
line. In addition, a similar threshold of –0.17 was identi-
fied by the SE of the measurements method.9
Exploratory efficacy analyses
SOBDA treatment group differences
After adjusting for age, sex and the SOBDA baseline score,
the difference between the FSC and placebo was –0.09
(95% CI −0.23 to 0.05) and between SAL and placebo, it
was 0.03 (95% CI −0.11 to 0.16).
CRQ-SAS
The greatest mean changes for dyspnoea and fatigue
were observed in the FSC group (0.4 and 0.3, respect-
ively). The mean changes from the baseline in emo-
tional function were similar between the placebo and
the two treatment groups (0.2 and 0.1), as were those
for mastery (0.2 for placebo, 0.3 for SAL and 0.4 for
FSC). The SAL and FSC groups reported a change of
‘better’ or ‘much better’ (56% and 65%, respectively)
compared with the placebo group (53%). Thirty-four
per cent of the patients receiving placebo were rated as
responders, whereas 37% of SAL patients and 46% of
FSC patients were responders using this measure.
Spirometry
The mean changes in FEV1 in the placebo, SAL and
FSC groups were 1, 61 and 138 mL, respectively. Forty
nine per cent of patients receiving FSC were considered
as responders, while 38% of patients receiving SAL and
25% of patients receiving placebo were responders. The
majority of the patients in the FSC (62%) and SAL
(55%) groups reported a change of ‘better’ or ‘much
better’, and less than half of the patients in the placebo
group (38%) reported this change.
Safety
AEs were reported for the 37 patients (27%) in the FSC
group, 34 patients (23%) in the SAL group and 14 patients
(19%) in the placebo group. COPD exacerbation, dys-
pnoea, headache and respiratory tract infection were the
most commonly reported AEs with no other individual
AEs occurring in ≥3% of patients in any group.
Twelve patients experienced serious AEs (SAEs; FSC, 3
[2%] patients; SAL, 5 [3%] patients; placebo, 4 [5%]
patients); three of these SAEs were considered possibly
related to study medication (SAL, 1 patient; placebo, 2
patients). One fatal SAE of respiratory failure occurred
for a patient receiving FSC during the study, but was not
considered to be related to the FSC treatment by the
study investigator.
DISCUSSION
SOBDA was developed to address the need for a robust
and psychometrically sound patient-reported outcomes
questionnaire for use in clinical research that would specif-
ically capture dyspnoea experienced with daily activities as
perceived by patients with COPD. The available question-
naires have limited assessment of the psychometric proper-
ties, inconsistent clinical validity and/or are not
dyspnoea-specific. The CRQ-SAS10–12 and SGRQ13 14 ques-
tionnaires, for example, measure multiple dimensions that
are much broader than dyspnoea with activity, which is the
specific aim of the current SOBDA questionnaire. The
mMRC questionnaire has been used to discriminate
between levels of dyspnoea associated with exercise, but
Table 2 Known groups validity: the least-squares mean baseline SOBDA weekly score by mMRC and CGI-S response
categories at visit 2
Response
categories
Patient-completed mMRC (n), LS
mean SOBDA score (SE)
Clinician-completed mMRC (n), LS
mean SOBDA score (SE)
CGI-S (n), LS mean
SOBDA score (SE)
0 12, 1.92 (0.19) – –
0–1 – 12, 1.78 (0.20) –
1 103, 1.94 (0.07) – 19, 1.87 (0.16)
2 138, 2.20 (0.06) 200, 2.08 (0.05) 236, 2.11 (0.05)
3 65, 2.26 (0.08) 117, 2.28 (0.06) 78, 2.33 (0.08)
4 22, 2.73 (0.14) 10, 2.73 (0.22) 5, 2.72 (0.31)
Owing to the small number of 0 and 1 responses in the clinician-completed mMRC, these two categories were combined.
CGI-S, Clinician Global Impression of Dyspnoea Severity; LS, least squares; mMRC, modified Medical Research Council; SOBDA, Shortness
of Breath with Daily Activities.
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shows very limited response to change in clinical trials due
to the limited number of categories for response.
This study confirms that the SOBDA questionnaire has
sound psychometric properties. The SOBDA weekly
scores had an internal consistency reliability of
Cronbach’s α value of 0.89, which surpassed the estab-
lished threshold goal of >0.7.7 SOBDA also had good
test–retest reliability (ICC=0.94), exceeding the thresh-
old goal of >0.60, in patients reporting no change in
their breathlessness as measured by the PGAC.15
The convergent validity assessed through the Spearman
rank order correlations was reasonable, although it was
lower than expected for CGI-C and mMRC. This may have
been due to the narrow range of responses given by clini-
cians: most patients were rated as ‘2’ or ‘3’ by clinicians on
both scales. The narrow range of clinician mMRC ratings
reflects the inclusion criteria requiring patients to have an
mMRC ≥2 at study entry. The CRQ-SAS dyspnoea scale,
which measures the concept most similar to SOBDA,
showed the highest correlation with the SOBDA question-
naire and is supportive of SOBDA’s construct validity.
The SOBDA weekly scores in the study population
demonstrated good known-groups validity through a
series of analyses. The scores were differentiated
between dyspnoea severity as rated by clinicians and
patients. As expected, discrimination based on patient
ratings was better than that based on clinician ratings.
Known-groups validity was also confirmed when compar-
ing SOBDA with CGI-S.
Assessment of responsiveness of the SOBDA question-
naire was conducted independent of treatment alloca-
tion. Good separation in the SOBDA weekly scores was
observed between the PGAC groups at day 8 as indicated
by significant differences between the scores for the
responders and the non-responders. Less separation was
observed between the PGAC groups throughout the
later weeks of the 6-week treatment period compared
with week 1. This diminished separation may be partially
explained by the way the PGAC score was derived, that
is, each week’s PGAC score was based on scores from the
previous week. This is also not an unexpected trend as
any improvement in dyspnoea would be expected to
occur or be perceptible to patients soon after initiating
therapy, with continued improvement being less notice-
able over time. The particularly diminished responsive-
ness observed at week 6 was potentially due to
approximately half of the patients not providing a
response to the PGAC at day 43 or at the last visit.
Changes from baseline in the SOBDA last treatment
week scores were statistically significant between respon-
ders and non-responders using the CGI-C and CRQ-SAS
dyspnoea domain, but not the mMRC. This again may
be due to the narrow range of the mMRC ratings.
The thresholds for the SOBDA responders and MID
were explored by using anchor-based and distribution-
based methods. Anchor-based methods were used to estab-
lish a preliminary MID range for SOBDA mean score
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as the threshold for the SOBDA responders to allow a com-
parison of the proportions of responders in different cat-
egories (eg, different interventions or treatments). The
evaluation of data around the MID was based on the
change from the baseline in the SOBDA score for those
patients who endorsed or had the clinician endorse for
them, (depending on the anchor), the response category
‘better’ for the global assessments or the prespecified
grouping of meaningful improvement on other measures
(PGAC, CGI-C, CRQ-SAS and FEV1). Based on these
anchors, a preliminary response threshold for the SOBDA
questionnaire is a −0.1 to −0.2 score change. This is
further supported by distribution-based estimations of the
MID using methods described by Revicki et al8 and
Wyrwich et al.9 Thus, a threshold of −0.1 to −0.2 for the
score range of 1–4, supported by anchor-based and
distribution-based methods, seems reasonable at this stage
of questionnaire development. This MID estimation is also
consistent in scale with that of the CRQ-SAS in which the
MID is 0.5 on a 7-point Likert scale.16
Exploratory analysis by treatment group suggested that
the proportion of patients crossing the −0.1 and −0.2
thresholds was numerically greater for the SAL group
compared with the placebo, and numerically greater for
the FSC group compared with the SAL group. As the
study was designed only to validate SOBDA and cannot
reliably demonstrate differences between treatment
groups, these changes from baseline in the SOBDA
weekly score at last treatment can only be regarded as
exploratory. Even after adjusting for age, gender and the
baseline SOBDA weekly score, the mean change in the
score for each treatment group when compared with
placebo did not meet the MID of −0.1 or −0.2.
This study had some limitations. Only patients with
mMRC ≥2 were included in the study, which restricted
the ranges of the dyspnoea severity. The effects of
exacerbation and possible cultural differences on the
study results were not evaluated. Finally, approximately
half of the patients did not answer the last PGAC ques-
tion despite completing other final visit assessments.
These limitations could have had an effect on some of
the results of our study, although we do not feel that
there would be any change to the overall conclusions.
In summary, this study demonstrates that the 13-item
SOBDA questionnaire is reliable, valid and responsive to
change in patients with COPD. At this stage of question-
naire development, a change score of −0.1 to −0.2 is the
most appropriate estimation for determining a threshold
for treatment response. A specific value will be identified
as more data are generated from future clinical trials.
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